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ABSTRACT
Chinnasamy, Swathee. M.S., Microbiology and Immunology
Program, Wright State University, 2011. Developing a
quantitative PCR assay for detecting viral vector
shedding from animals.

Replication deficient viruses have been used widely
for replacing, repairing, and deleting target genes.
These recombinant viruses are tested on research animals
or patients in clinical trials. Although viral vectors
distribute in the body, they are also disseminated into
the environment through secretion and excretion
processes. By studying the extent of shedding, a proper
risk assessment can be performed and appropriate
biocontainment can be achieved.
Adenoviral and lentiviral vectors were produced from
commercially available kits. The transgene present in
both vector systems was the lacZ reporter gene encoding
for β-galactosidase. Primers and probes were designed for
the encapsidation region of the adenoviral vector and the
Rev Response Element (RRE) of the lentiviral vector to
iii

detect the viral vectors by Q-PCR. Internal control
sequences were also designed and synthesized for both
systems. Standard curves were generated using five 10fold serial dilutions. Singleplex reactions confirmed the
specificity of the probes on the viral DNA and the
quality control sequences. A comparison of singleplex
with multiplex data was performed to validate the assay.
The assay was used to quantify the total virus genome
count (vg) present in adenoviral and lentiviral stocks.
The vg counts were compared to the infectious titers in
order to gauge the quality of the virus stocks. For the
lentivirus stock, a second confirmatory assay was made by
p24 assay using enzyme linked immunosorbent assay to
validate the Q-PCR results. The efficiency of cDNA
synthesis (to convert the lentiviral RNA into cDNA for QPCR) was determined to be 20% on average.
Overall, a highly specific and sensitive Q-PCR assay
was developed that will enable researchers to quantify
the amount of adenoviral and lentiviral vector shedding
from infected animal hosts. This assay will help to
determine proper housing requirements for research
animals and improve worker safety.

iv
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II. INTRODUCTION:

Gene therapy is a potential form of treatment for a
variety of acquired and inherited diseases. The therapy
involves introducing genetic material into target cells to
slow a disease process or cure a particular condition. The
treatment is accomplished by using gene transfer vectors
that can 1ittering1 different cells, organs, or tissues.
Vectors can be engineered to possess a variety of
desirable characteristics, such as having the ability to be
produced in large quantity and concentrated form, to
1ittering1 different cell types (both dividing and nondividing cells), to be stably expressed (either by
integration into host DNA or by formation of an episome),
and to avoid unwanted immune responses.
Gene delivery may be classified into two categories:
non-viral and viral. The non-viral gene delivery methods
include chemical transfection, lipofection, or
electroporation of naked DNA. Although naked DNA vectors
have the advantage of being produced in high concentration
and eliciting less immune response, they suffer from
transient gene expression and inefficient gene transfer.
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Viral vectors provide a more efficient way of
transferring a desired gene into target cells since they
have naturally evolved to deliver their own RNA or DNA
genomes into host cells (Verma & Weitzman, 2005). In
general, viruses are capable of inserting their genetic
material into host cells for replication and have evolved
over time to escape host immune responses. One strategy for
gene therapy is to replace some of the viral genes with the
desired foreign genes (transgenes) and to engineer the
virus to 2ittering2 a desired target cell population. Some
viruses that are commonly used as vectors include
adenovirus, lentivirus, retrovirus, adeno-associated virus,
and herpes simplex virus (Warnock, Daigre, & Al-Rubeai,
2011).

Adenovirus as a vector:
Adenoviruses represent the largest non-enveloped
viruses, having achieved the largest size that can be
transported via endosomes. The virus structure is comprised
of an icosahedral capsid and double-stranded DNA genome of
about 26-45 kb (Volpers & Kochanek, 2004). Adenovirus was
originally isolated in 1953 from adenoid tissue. Since
then, more than 50 serotypes have been discovered and also
classified into six species A-F (Warnock et al., 2011).
2

They cause upper respiratory diseases, bladder infections,
and gastroenteritis, depending on the serotype.
Adenovirus capsids have a pentameric penton base
protein from which the trimeric fiber protein extends into
a globular knob domain. The virus attaches to its cellular
receptor using the globular knob domain of the fiber
protein (Volpers & Kochanek, 2004). Depending on the
serotype, adenoviruses use a variety of cellular receptors,
including the Coxsackie-Adenovirus receptor, other
immunoglobulin superfamily proteins, integrins, 3itteri
sulfate glycosaminoglycans, cluster of differentiation
antigens, sialic acid, and other proteins and non-protein
molecules (Zhang & Bergelson, 2005). The
arginylglycylaspartic acid tripeptide (RGD) motif in the
penton base protein interacts with surface integrin
molecules of the cell, leading to internalization of the
virus by means of clathrin-dependent receptor mediated
endocytosis. Following the internalization of the virus,
the capsid is dismantled in the cytoplasm and the core
protein-coated viral genome is transported in to the
nucleus (Russell, 2009).
The Adenovirus genome consists of two regions for
transcription—the early and the late regions. The early
region contains four transcription units. The first gene
3

transcribed is E1A, which codes for a transactivator
protein for the other early region genes, E1B, E2, E3 and
E4. The E2 gene codes for DNA polymerase, preterminal
protein, and DNA binding protein, which are required for
viral replication. The E3 region encodes for proteins that
have anti-immune functions. The E4 region encodes for
proteins involved in mRNA transport and splicing (Warnock
et al., 2011). Adenovirus type 5 (Ad5) is the most commonly
used serotype for vector design. First generation vectors
have the E1 and E3 genes deleted, thus preventing the virus
from replicating and providing space for foreign gene
insertion. Since the E1 gene is essential for replication,
the vectors must be complemented. This is generally
accomplished by using the human embryonic kidney cell line
named 293, which expresses E1 proteins (Bett et al., 1994).
This system allows for high titers to be produced, but the
lack of E3 causes the virus to be cleared from the system
due to the host immune response, thus leading to short
duration of transgene expression. A major limitation of
adenoviral vectors it is that they induce inflammation, are
neutralized by host antibodies, and exhibit short term
expression of transgenes (Kovesdi et al., 1997).
Two approaches have been traditionally used to
generate recombinant adenovirus vectors. The first method
4

has been to directly ligate the gene of interest into the
adenoviral genome. This method turned challenging as the
virus is large and there were not many unique restriction
sites. Another approach was developed where the gene of
interest is cloned into a shuttle vector followed by
transferring the gene into the virus genome via homologous
recombination in mammalian packaging cell lines. The
disadvantage here is that defective adenovirus was
produced, and the screening and purification of plaques and
repeated purification was laborious (Mittal et al. 1993;
Stratford-Perricaudet, et al. 1992).
Later, a method to reduce the time consumption for
producing a recombinant adenovirus was introduced that
utilized the homologous recombination carried out in
prokaryotic cells (bacteria), giving a better selection
system (He et al., 1998). The recombinant adenovirus is
produced by a double recombination process between a
plasmid vector, which has an adenoviral backbone, and a
shuttle vector, which carries the gene of interest. To
avoid the background caused by non-recombinant shuttle
plasmid, the bacteria are pre-transformed with the plasmid.
The recombinant adenovirus is selected by resistance to
antibiotic. The recombinant adenovirus is then packaged in
mammalian cell lines which complement with the E1 gene in
5

trans that is required for replication. This system has
been commercialized by Agilent Technologies (formerly
Stratagene) as the AdEasyTM system.

Lentivirus as a vector:
Although retroviruses in the Gammaretrovirus genus of
the Retroviridae family had been used widely for delivering
genes into target cells, they had the disadvantage of not
being able to infect the non-dividing cells. When it was
discovered that viruses in the Lentivirus genus of the
Retroviridae family contained nuclear localization signals
on the Matrix, Vpr, and Integrase proteins that allow them
to cross the nuclear membrane in the absence of mitosis,
interest grew in developing lentiviral vectors for gene
delivery.
One of the most commonly studied lentiviruses is HIV1. Some of the other lentiviruses include Bovine
immunodeficiency virus (BIV), Simian immunodeficiency virus
(SIV) and Feline immunodeficiency virus (FIV). The genome
organization of HIV-1 is similar to that of other
retroviruses, but it has additional regulatory and
accessory genes that lead to a more complex replication
cycle. Its RNA genome is about 10 kb and its capsid is
6

about 100 nm in diameter (Volpers et al., 2004). The HIV-1
regulatory proteins are Tat and Rev. The former helps the
viral RNA to be produced by activating the viral promoter.
The Rev protein promotes the transport of unspliced RNA
from the nucleus to the cytoplasm by interacting with the
Rev responsive element (RRE) present on the viral RNA.
In general, retroviruses enter cells by fusion with
the plasma membrane. The exact mechanism of uncoating is
unclear. Reverse transcription takes place in the
cytoplasm, and the double-stranded DNA intermediate is
transported to the nucleus where it integrates into the
host chromosome. At this point, the virus is under control
of the cellular transcription machinery.
Many of the early HIV vectors were almost intact viral
genomes having deletions in the env gene, which was
provided in trans. Use of the wild-type HIV Env limited the
target cell population to CD4+ cells. Replacing the HIV Env
with other viral envelope proteins (such as VSV-G, MLV
amphotropic envelope glycoprotein) resulted in a wider
target of cell types and higher titer values.
The chances of producing a replication competent
virus was reduced by producing the second and third
generation vectors and also the self inactivating
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lentivirus vector (SIN) (Dull et al., 1998; Miyoshi et al.,
1998; Zufferey et al., 1998). Separate plasmids were used
in all these vector systems for envelope genes and
packaging genes, but the third generation system uses a
fourth plasmid encoding the rev gene in addition to the
above features. The third generation vectors had the Tat
dependent promoter replaced with Rous sarcoma virus (RSV)
promoter. Thus, the most widely used lentiviral vectors are
the third generation vectors since they reduce the sequence
homology with the wild type HIV (Dull et al., 1998).

Biodistribution of Adenoviral and Lentiviral vectors:
Therapeutic effect is achieved on a pathological
process by means of gene transfer to a target tissue.
Possible expression of the transgene in non-target tissue
is a drawback for gene therapy. One of the main
characteristic features to be studied for a vector used in
gene therapy is biodistribution in tissues (Pan et al.,
2002). Biodistribution study aims at defining areas where
the vector spreads, target organs for toxicity, and
germline transmission risk assessment. Some of the commonly
studied organs are heart, brain, liver, spleen, kidney,
lungs. One of the most widely used methods to detect
8

toxicity based on genetic material transferred is
quantitative PCR (Q-PCR). Prior to clinical trial, these
studies are generally conducted on cell lines and in animal
models (Hiltunen et al., 2000).
Adenoviral vector biodistribution has been
studied previously, and it was found to be predominantly
expressed in the liver when injected into mice through
intravenous route (IV, tail vein injection) (Alemany, et
al. 2000; Wood et al., 1999). The IV route also resulted in
expression in most organs, including the lung, kidney,
heart, and spleen. A study involving the distribution of
the human-multi drug resistance gene (MDR1) was evaluated
using the mice colon carcinoma model, in which the
adenovirus was administered by bone marrow transplantation.
By means of in situ hybridization and immunohistochemistry,
they demonstrated that the vector was expressed in the
lung, kidney, intestine, and bone marrow cells, and not in
the liver, spleen, brain, or tumor (Zhao et al., 2010).
Hiltunen et al. (2000) showed that biodistribution
depended on the route of administration. They administered
adenovirus vector virus to rabbits through periadventitial
and intravascular routes and showed that both methods lead
to systemic leakage of virus and expression in non-target
organs such as the bone marrow, liver, skeletal muscle, and
9

testis. Less leakage was observed with the periadventitial
delivery route. Biodistribution is followed by shedding and
the data for both are required for analyzing the safety
profile (Tiesjema, et al. 2010).

Shedding via Excretion:
The dissemination of viral vector into the environment
by means of excreta is referred as shedding. It is
considered a major risk factor to the environment and
therefore shedding analysis of urine and feces are
performed. Again, shedding depends on the route of
administration since it leads to biodistribution to those
organs from where it sheds. Three possible routes have been
studied for shedding via urine and they are through blood
and kidney, from bladder and from prostrate through the
ureter. Biodistribution of the virus to the liver and
secretion of bile remains as a possible route for shedding
via feces. Kawahira et al (2009), in their analysis of
adenoviral shedding after esophagus cancer treatment,
showed that 29.7% percentage of patients were positive for
shedding via feces and also 10% patients showed positive
for shedding via urine, suggesting that gastrointestine can
be a possible route for shedding. Treatment of lung cancer
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with adenoviral vector also showed positive stool samples
(Griscelli et al., 2003). The I.V route leading to
biodistribution to kidney acts as a possible route for
adenoviral vector shedding through urine and other routes
include intra-prostatic and intramuscular. (Tiesjema et
al., 2010).
Quantification of the shedding is performed using QPCR. Some of the other methods include conventional PCR and
transgene expression. In case of patients treated with
viral vectors the potential for transmission to third
parties needs to be considered if shedding is observed.
Other factors to be considered are that shedding is time
and dose dependent. One of the most important parameters
for performing successful Q-PCR is the use of a control,
which is sometimes spiked into the actual test sample, for
checking inhibition, specificity, and sensitivity of the
reaction. Reactions for Q-PCR are often performed in
duplicate or triplicate to increase accuracy (Gonin &
Gaillard, 2004). The technique of using an internal control
in the same reaction tube (multiplexing) offers the
advantage of greater accuracy, but this control can also
compete against the amplification, if not chosen carefully
and validated.
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III. MATERIALS AND METHODS:

Vector production:
Adenoviral vector:
The Ad EasyTM XL Adenoviral vector system (Agilent
Technologies, Santa clara, CA) was used for the production
of adenoviral vector using the manufacturer’s instruction.
The following is a brief description of the protocol.
The pshuttle-CMV-lacZ vector encoding the gene for βgalactosidase was linearized with the enzyme PmeI (New
England Biolabs, Ipswich, MA) and transformed into BJ5183AD-1 competent cells and plated. The smallest colonies were
chosen. DNA was isolated, checked for the desired size, and
transformed into the XL-10 Gold cells for amplification of
the plasmid. Individual colonies from the transformation
reaction were selected and restricted with PacI (New
England Biolabs) and analyzed for the correct restriction
pattern. A maxi prep (QIAGEN, Valencia, CA) was performed
to isolate a large amount of plasmid DNA from a large
culture, and it was stored at 4°C. Plasmid DNA for
transfection was restricted PacI (New England Biolabs,
Ipswich, MA) and purified using the StrataPrep PCR
Purification Kit (Agilent Technologies). The AD-293 cell
12

line was established and passaged as per the manufacturer’s
instruction. This cell line was used for transfection of
the recombinant Ad5 plasmid to produce recombinant
adenovirus. The primary viral stocks were produced, stored
at -70°C, and 13itterin using a plaque assay. A second
round of infection was performed on the cells to amplify
the viral stock which was then purified and concentrated on
a binding column using the AdEasy Purification kit (Agilent
Technologies). The stocks were 13itterin again using plaque
assay.
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pshuttle
-CMVlacZ.

Linerarized with PmeI

Transformed into of BJ-5183-AD-1 cells
Homologous recombination occurs
Amplification of recombinant DNA with XL-10 gold cells

DNA digested with PacI to give linearized recombinant DNA

Ad-293 cells transfected

Virus produced, followed by titering virus
Fig 1: An outline of the steps involved in the Ad EasyTM XL
Adenoviral vector system.
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Lentiviral vector:
The lentiviral (HIV) vector was produced using pLenti
6.3/V-5 DEST kit (Invitrogen, Carlsbad, CA). The vector
containing the lacZ gene with pLenti-DEST was transformed
into One Shot Stbl3TM cells that were provided with the kit
and plated. Colonies were selected and cultured for plasmid
isolation using a mini prep kit (QIAGEN). Restriction with
XhoI (New England Biolabs) enzyme was performed to confirm
the presence of the correct DNA size. This DNA was used to
transform XL-10 gold cells, selected on agar plates
containing kanamycin, and cultured. Plasmid DNA was
isolated by maxi prep (QIAGEN). It was restricted with XhoI
(New England Biolabs) to confirm the restriction pattern.
The restricted DNA was used to transfect the 293FT cell
line along with the ViraPower Lentiviral Expression Systems
(Invitrogen) to produce recombinant lentiviral vector
virus.

15

pLenti
6.3/v5GW/lacZ

Transformed into One Shot Stbl3™

DNA is amplified by transformation into XL-10 gold cells.

Virapower packaging
mix
Co-transfection of 293FT cell line

Virus produced, followed by 16ittering the virus

Fig 2: An outline of the steps involved in the pLenti
6.3/V-5 DEST kit.
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Adenoviral primers and probes:
The wild type probe for the adenoviral vector was
labeled at the 5ʹ end with reporter dye molecule 6carboxyfluorescein (6-FAM) whose emission wavelength is 520
nm and at the 3ʹ end with Black Hole Quencher-1 with a
quenching wavelength between 520 and 583 nm. The QC probe
for the adenoviral vector was labeled at the 5ʹ end with
reporter dye molecule 6-carboxyfluorescein-4’,5’-dichloro2’,7’-dimethoxyfluorescein (JOE) whose emission wavelength
is 555 nm and at the 3ʹ end with Black Hole Quencher-2 with
a quenching wavelength between 550 and 668 nm. For
detection of the encapsidation region which starts at 183
bp in the adenoviral vector, the primers were designed
using MacVector software to yield a final amplicon of 116
bp.
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TABLE 1: SEQUENCE INFORMATION OF PRIMERS/PROBES USED FOR
ADENOVIRAL VECTOR.

PRIMER/PROBE

SEQUENCE

NUMBER OF MELTING
BASEPAIRS TEMPERATURE

FORWARD
PRIMER

5ʹ-ACA GGA AGT GAC AAT
TTT CGC-3ʹ

21

66.0°C

REVERSE
PRIMER

5ʹ-TCA GAT TTC ACT TCC
TCT TAT TCA G-3ʹ

25

64.69°C

PAdEASY WT
PROBE

5ʹ-/56-FAM/ACT CGG TTA
CGC CCA AAT TTA CTA
CAA CAT/3BHQ -1/-3ʹ

30

71.62°C

CONTROL
SEQUENCE
PROBE

5ʹ-/56-JOEN/ ACT ATG
CCA CGC TCA CAT GTA
TTA CAT CGT/3BHQ-1/-3ʹ

30

72.65°C
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Encapsidation Start
|
166
176
|186
196
206
216
226
*
*
| *
*
*
*
*
GATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTA
CTACACCGTTTTCACTGCAAAAACCACACGCGGCCACATGTGTCCTTCACTGTTAAAAGCGCGCCAAAAT

236
246
256
266
276
286
296
*
*
*
*
*
*
*
GGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAG
CCGCCTACAACATCATTTAAACCCGCATTGGCTCATTCTAAACCGGTAAAAGCGCCCTTTTGACTTATTC

306
316
326
336
*
*
*
*
AGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAA
TCCTTCACTTTAGACTTATTAAAACACAATGAGTATCGCGCATT
|
|
Encapsidation End

Fig 3: Sequence of Wild Type adenoviral encapsidation region.
The sequence of the encapsidation region on the adenoviral vector for which the primers
and probe were designed. Sequences in red : forward and reverse primers and the probe
sequences are double underlined.
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Encapsidation Start
|
166
176
|186
196
206
216
226
*
*
| *
*
*
*
*
GATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTA
CTACACCGTTTTCACTGCAAAAACCACACGCGGCCACATGTGTCCTTCACTGTTAAAAGCGCGCCAAAAT

236
246
256
266
276
286
296
*
*
*
*
*
*
*
GGCGGACGATGTAATACATGTGAGCGTGGCATAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAG
CCGCCTGCTACATTATGTACACTCGCACCGTATCATTCTAAACCGGTAAAAGCGCCCTTTTGACTTATTC

306
316
326
336
*
*
*
*
AGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAA
TCCTTCACTTTAGACTTATTAAAACACAATGAGTATCGCGCATT
|
|
Encapsidation End

Fig 4: Sequence of Adenoviral vector Synthetic Fragment (Quality Control).
The sequences in red indicate the forward and reverse primers; the probe sequences are
double underlined and the mutated base pairs are indicated in BOLD. This entire region
was inserted into pIDTSMART (Integrated DNA technologies, San Jose, CA).
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Lentiviral primers and probes:
Similar to the adenovirus system, the probe for the
wild type lentiviral vector was labeled at the 5ʹend with
6-FAM and at the 3ʹ end BHQ-1, whereas the probe for the
lentiviral QC sequence was labeled at the 5’ end with JOE
and at the 3’ end with BHQ-2. The region for detection was
the Rev Responsive Element (RRE) starting at 1075 bp of the
lentiviral vector. For detection of the HIV RRE region,
which starts at 1075 bp in the HIV vector, the primers were
designed using MacVector software to yield a final amplicon
of 111 bp.
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TABLE 2: SEQUENCE INFORMATION OF PRIMERS/PROBES USED FOR
LENTIVIRAL VECTOR.
PRIMER/PROBE

SEQUENCE

NUMBER OF MELTING
BASEPAIRS TEMPERATURE

FORWARD
PRIMER

5ʹ-TCA ATG ACG CTG
ACG GTA C-3ʹ

19

65.28°C

REVERSE
PRIMER

5ʹ /GAC TGT GAG TTG
CAA CAG ATG/3ʹ

21

63.88°C

p Lenti RRE
WT PROBE

5ʹ/56- FAM/ TGT TCT
GCT GCT GCA CTA TAC
CAG ACA/3BHQ- 2/3ʹ

27

71.84°C

CONTROL
SEQUENCE
PROBE

5ʹ/56- JOEN/TGC TCT
ACC ACT GAA CTC TAC
GAG TCT/3BHQ-2/3ʹ

27

72.26°C
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RRE Start
|
|
1084
1094
1104
1114
1124
1134
1144
|
*
*
*
*
*
*
*
AGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACG
TCCTCGAAACAAGGAACCCAAGAACCCTCGTCGTCCTTCGTGATACCCGCGTCGCAGTTACTGCGACTGC
1154
1164
1174
1184
1194
1204
1214
*
*
*
*
*
*
*
GTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGC
CATGTCCGGTCTGTTAATAACAGACCATATCACGTCGTCGTCTTGTTAAACGACTCCCGATAACTCCGCG
1224
1234
1244
1254
1264
1274
1284
*
*
*
*
*
*
*
AACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAG
TTGTCGTAGACAACGTTGAGTGTCAGACCCCGTAGTTCGTCGAGGTCCGTTCTTAGGACCGACACCTTTC
RRE End
1294
1304
|
*
*
|
ATACCTAAAGGATCAACAGCTCCT
TATGGATTTCCTAGTTGTCGAGGA

Fig 5: Sequence of Wild Type HIV RRE region. The sequence of the RRE region on the
lentiviral vector for which the primers and probe were designed. Sequences in red :
forward and reverse primers and the probe sequences are double underlined.
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RRE Start
|
|
1084
1094
1104
1114
1124
1134
1144
|
*
*
*
*
*
*
*
AGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACG
TCCTCGAAACAAGGAACCCAAGAACCCTCGTCGTCCTTCGTGATACCCGCGTCGCAGTTACTGCGACTGC
1154
1164
1174
1184
1194
1204
1214
*
*
*
*
*
*
*
GTACAGGCCAGACAATTATAGACTCGTAGAGTTCAGTGGTAGAGCAATTTGCTGAGGGCTATTGAGGCGC
CATGTCCGGTCTGTTAATATCTGAGCATCTCAAGTCACCATCTCGTTAAACGACTCCCGATAACTCCGCG
1224
1234
1244
1254
1264
1274
1284
*
*
*
*
*
*
*
AACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAG
TTGTCGTAGACAACGTTGAGTGTCAGACCCCGTAGTTCGTCGAGGTCCGTTCTTAGGACCGACACCTTTC
RRE End
1294
1304
|
*
*
|
ATACCTAAAGGATCAACAGCTCCT
TATGGATTTCCTAGTTGTCGAGGA

Fig 6: Sequence of HIV Synthetic Fragment (Quality Control).
The sequences in red: forward and reverse primers; the probe sequences are double
underlined and the mutated base pairs are indicated in BOLD. This entire region was
inserted into pIDTBLUE (Integrated DNA Technologies).
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Quality control (QC) sequences:
Quality control sequences were designed for both adenoviral
and lentiviral vectors by incorporating specific mutations
into the probe region of the synthetic molecule to allow
differential detection in PCR. Restriction sites NcoI and
PstI for adenoviral and XhoI and NotI for lentiviral
control sequence were engineered at the ends of the
synthetic molecules for cloning. The adenoviral QC sequence
was cloned into the pIDTSMART vector, while the lentiviral
QC sequence was cloned into pIDTBlue vector (Integrated DNA
Technologies), the latter being an in vitro transcription
vector.
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A)

B)

Fig 7: Quality control sequence inserted into plasmids by
IDT.
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Region in Blue is the QC sequence flanked by restriction
sites A) QC plasmid for adenoviral vector; B) QC plasmid
for lentiviral vector.

RNA production and isolation:
The lentiviral QC sequence was in vitro transcribed
using the RiboMAX Large Scale RNA Production System
(Promega, Madison, WI). The pIDTBlue vector DNA containing
the lentiviral QC sequence was extracted with a
phenol:chloroform mixture to enhance cutting with NotI (New
England Biolabs). The restricted DNA was separated from
uncut DNA by overnight gel electrophoresis using constant
amperage of 30 mA, 1.5% agarose gel, and Tris-boric acidEDTA buffer. The desired linearized plasmid of 3,139 bp was
excised from the gel and purified using QIAquick extraction
kit (QIAGEN). The in vitro transcription reaction was
performed using the gel purified plasmid DNA, T7
polymerase, and other RiboMAX reagents at 37°C for four
hours. To remove input DNA, RNase-free Dnase was added at a
concentration of one unit per microgram of input DNA and
incubated at 37°C for 15 minutes. The RNA was purified
using SV RNA Isolation System (Promega) following the
manufacturer’s instructions. The purified RNA was analyzed
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for size, purity, and concentration by electrophoresis on a
1% native agarose gel using Tris-acetic acid, EDTA buffer.
The RNA was further quantified by UV spectrometry,
aliquoted, and stored at -70°C.

RT-PCR:
The RNA was converted to cDNA using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems,
Carlsbad, CA) in accordance with manufacturer’s
instructions. Serial 10-fold dilutions of the RNA were made
such that there was a range of 1 to 106 molecules per cDNA
reaction. The reaction conditions were 10 minutes at 25°C,
120 minutes at 37°C, 5 minutes at 85°C and ∞ at 4°C. This
cDNA was used in Q-PCR to determine the reverse
transcription efficiency.

Quantitative PCR (Q-PCR):
For quantitative PCR analysis of adenovirus and
lentivirus genomes, primers and probes were synthesized by
IDT (Integrated DNA Technologies). The reactions were
performed on the ABI Prism 7900 HT sequence detection
system under the following reaction conditions: 1 cycle at
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50°C for 2 min, 1 cycle at 95°C for 10 min, and 40 cycles
at 95°C for 15 sec and 60°C for 60 sec. A set of DNA
standards were produced that corresponded to 106,105,104,103
and 102 molecules per Q-PCR reaction. The standards were
created by diluting the wild type and quality control
plasmid DNAs of the Adenovirus and HIV-1 vectors. The
dilution buffer was 10 mM Tris, 1 mM EDTA, pH 7.5. The
final Q-PCR reaction volume was 20 µl and contained the
proprietary TaqMan mix (Applied Biosystems, Carlsbad, CA),
which provided all of the necessary reagents for
amplification. Primers were used at concentrations of 18 µM
and probes were used at concentrations of 2.5 µM. The
graphs and statistical analyses for the standard curves
were plotted using SigmaPlot 11.2 software (Systat Software,
Inc., San Jose, CA).

p24 Assay:
The p24 assay was performed using Retrotek HIV-1 p24
Antigen ELISA kit (Zeptometrix Corporation, Buffalo, NY) by
following the manufacturer’s protocol.
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III.RESULTS
Successful construction of Adenoviral vector:
Generation of recombinant Ad plasmid:
The Ad EasyTM XL Adenoviral vector system (Agilent
Technologies) makes use of the first generation adenoviral
vector system. The two sets of early region genes, E1 and
E3, are deleted in this system. The E1 region is required
for replication of virus. However, it is provided in trans
by the AD-293 cells. The recombinant adenoviral plasmid was
constructed by transforming the BJ5183-AD-1 competent cells
with linearized shuttle vector pshuttle-CMV-LacZ and pAd
Easy vector-1. Both the shuttle vector and pAd Easy-1 have
the right arm and the left arm regions that provide
sequence homology for the process of homologous
recombination. The transformed cells were plated and the
smallest colonies were chosen and cultured. The
recombination was confirmed by isolating the plasmid DNA,
restricting with PacI (New England Biolabs) and loading
onto an agarose gel to visualize a 3.0 kb band showing the
recombination occurred between the left and right arms.
This DNA was used for amplification of the plasmid using
XL-10 gold cells and following a similar selection process,
the 3.0 kb band on the gel was observed.
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Viral Vector Production:
Adenovirus was produced by transfection of AD-293
cells with plasmid DNA. After transfection of cells with
linearized plasmid DNA, virus was harvested from cells
after 8 days for a primary viral stock. The titer of the
viral stock was determined by plaque assay. Cells were
infected with serial 10-fold dilutions of virus stock in
duplicate and overlaid with agarose. Visible plaques
appeared after about one week, and they were counted on day
20 post-infection. Using this primary stock, one more round
of infection was performed to achieve an increase in viral
titer. For this amplification, the virus was harvested
after 24-48 hr. The viral stocks were then purified and
concentrated by the AdEasy Purification kit (Agilent
Technologies). To determine the titer of the stock, a
plaque assay was again performed. Two adenovirus stocks
were made and had titers of 6 x 107 and 4 x 108 pfu/ml.

Successful construction of Lentiviral Vector:
The HiPerform™ Lentiviral Expression System
(Invitrogen) was used and represents a third generation
lentiviral vector system. It comprises four plasmids—one
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vector and three helper plasmids. This reduces the chance
of producing replication competent virus. The regulatory
and accessory genes of HIV coding for as Tat, Rev, Vif,
Vpr, Vpu, and Nef are deleted from the vector plasmid, and
the third helper plasmid contains VSV-G (Vesicular
stomatitis virus envelope protein) replacing the env gene
(Dull et al., 1998). The vector, which expresses the lacZ
gene encoding for β-galactosidase, was transformed into One
shot Stbl3 ™ bacteria, selected, and cultured. DNA was
isolated and restricted with AflII and XhoI to confirm
integrity. This plasmid was used along with ViraPower™
Packaging Mixture (Invitrogen) to transfect 293FT cells to
produce virus. The expression system supplies replication
and structural proteins for producing the viral vector.
Viral stock was obtained and its titer was determined by
using HT1080 cells. These cells were transduced with 10fold serial dilutions and placed under blasticidin
selection 48 hours post-transduction. They were stained
with crystal violet after 10 days, and the stained colonies
were counted. The final viral stock had a concentration of
1 x 107 pfu/ml.
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Assay Design:
Primers and probes were designed from the DNA sequence
of the adenoviral and lentiviral vectors. These primers and
probes were designed in a manner that they can be used
universally for the current generation of vectors. For
adenoviral vectors, they were designed for the
encapsidation region. For the lentiviral vector, primers
and probes were designed in the Rev Response Element (RRE)
region. An internal control was also designed for both the
vectors.

Generation of quality control sequence templates:
Quality control sequences were designed such that the
region of probe binding in the encapsidation region of
adenoviral vector had 10 sequence differences; the RRE
region of lentiviral vector had 8 differences. They were
further designed such that the melting temperatures were
nearly identical. These sequences were cloned into two
different plasmids for both vectors. These plasmids were
transformed into bacteria for large scale production. The
plasmids were serially diluted for the use as standards
alongside the wild type standards for quantification
purposes.
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The quality control sequence DNA of lentiviral vector
was converted to RNA, since the genetic material of
lentiviral vector is RNA. For the conversion, the DNA was
extracted with phenol:cholorform for efficient restriction.
It was restricted by Not I to create a 3’ end to terminate
transcription. Insufficient cutting was observed when the
plasmid DNA by itself was restricted using Not I and
separated on an agarose gel. Therefore, the plasmid DNA was
extracted twice using phenol:cholorform and then
restricted. This resulted in more efficient cutting of the
DNA.

The restricted DNA was loaded onto an agarose gel

(Fig 8). The desired band was purified and transcribed into
RNA by using RiboMAX™ Large Scale RNA Production System
(Promega). The RNA was purified using the SV RNA isolation
system (Promega), analyzed by agarose gel electrophroesis,
and quantified by spectophotometry. A single RNA species of
296 bases was produced (Fig. 9). The RNA was diluted to a
concentration of 1 x 1011 molecules/μl, aliquoted, and
stored at -70°C for later use as a control.
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Fig 8: Agarose gel analysis of lentiviral quality control
sequence DNA after restriction.
Quality control sequence DNA of lentiviral vector
restricted with Not I after it was extracted twice by
phenol:choloroform. Lane 1: Uncut pLenti RRE QC DNA; Lanes
2,4,5: Restricted pLenti RRE QC DNA showing 3.1 kb band;
Lane 3: 1kb DNA Ladder.
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Fig 9: Agarose gel analysis of purified RNA control.

Lane 1: Low Range ss RNA Ladder; Lanes 2: Purified QC RNA;
Lane 3: Transcriptional control (1,800 bases).
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Generation of standards:
Ten-fold serial dilutions (representing 106 to
102 molecules per microliter) of vector DNAs and the quality
control sequences were amplified by Q-PCR in duplicate. A
singleplex reaction was performed in which a single
template was amplified using one set of primers/probe. The
DNA was amplified, quantified, and compared to a known
input number. The copy number of the DNA was equal to the
input number and optimized as standards. Slopes between
-3.1 and -3.6 with efficiencies of reactions between 90%
and 110% and with R2 values between 0.990 and 1.00 were
acceptable.
Assay specificity:
The specificity of the probes was checked by
amplifying the five serial dilutions of wild type DNA with
QC primers/probe and the QC DNA with wild type
primers/probe in separate wells on the plate and they were
compared to the standards. There was no amplification in
either of them, thus confirming their specificity.
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Sensitivity of the assay:
The reactions were performed in multiplex i.e.
the primers/probes were for both the wild-type and the
control sequence plasmids but with only one of the
templates (wt or QC) in the same well on the plate. The
template was amplified and they were compared to the
standards. There was no change in the sensitivity of the
assay i.e. the probes did not inhibit each other. These
reactions were checked separately for both adenoviral and
lentiviral vectors.
Another multiplex reaction was performed: the
primers/probes of both the wt and QC sequences were
amplified with both wt and QC templates in the same well.
Graphs were plotted showing their slopes, Ct values and
efficiencies (Fig 10 & Fig 13). The Ct (cycle threshold) is
the number of cycles required for the fluorescent signal to
cross the established baseline level.

Validation of the assay:
The singleplex and multiplex reactions were
compared to validate the assay. Ct values for the wild type
template of the vector from both singleplex and multiplex
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were compared (Fig 11; Fig 14). Similarly, the Ct values of
quality control sequence template were also compared (Fig
12; Fig 15). The Ct difference is calculated and a value
less than 1 was acceptable.

Standard graphs for adenoviral vector:
The graphs indicate that the primers/probes for
both the wild-type and control sequence are highly specific
and the templates were optimized as standards.
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Fig 10: Standard calibration curve of multiplex adenoviral
vector.
Quantitative PCR analysis for the adenoviral wild-type and
control sequence (multiplex). Five 10-fold serial dilutions
were used for the curve and the x-axis of the graph is the
Ct values against the copy numbers on the y-axis. The Ct
difference between them was less than one. The values of R2,
efficiency and slope fall within the standard required
number.
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Fig 11: Standard curve of adenovirus Wild-type Sequence.
To validate the multiplex assay format, Singleplex Vs
Multiplex Ct values were compared for adenoviral vector
wild-type sequence which was analyzed on Q-PCR. The
efficiency, R2 and the slope of the wild type in singleplex
was the same as in multiplex with their average Ct
difference being 0.19.
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Fig 12: Standard curve of adenovirus quality control

sequence.
To validate the multiplex assay format, singleplex Vs
Multiplex Ct values were compared for adenoviral vector
control sequence plasmid which was analyzed on Q-PCR. The
values of R2, Efficiency and slope for QC were almost close
numbers in both the singleplex and multiplex although the
average Ct difference between the two was calculated to be
0.39.
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Standard graphs for lentiviral vector:
The statistics from the graph indicate high
specificity for the primers/probes to the templates of
wild-type and control sequence.
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Fig 13: Standard calibration curve of multiplex lentiviral
vector.
Quantitative PCR analysis for the lentiviral wild-type and
control sequence (multiplex). Five 10-fold serial dilutions
were used for the curve and the x-axis of the graph is the
Ct values against the copy numbers on the y-axis. The Ct
difference between them was less than one. The values of R2,
efficiency and slope fall within the standard required
number.
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Fig 14: Standard calibration curve of lentiviral vector
Wild-type Sequence.
To validate the multiplex assay format, singleplex Vs
Multiplex Ct values were compared for wild-type sequence
which was analyzed on Q-PCR. The values of R2, Efficiency
and slope were almost the same for the wild type template
in singleplex and multiplex with an average Ct difference
of 0.14.
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Fig 15: Standard curve of lentivirus QC Sequence.
To validate the multiplex assay format, singleplex Vs
Multiplex Ct values were compared for control sequence
which was analyzed on Q-PCR. The values of R2, Efficiency
and slope were close numbers in singleplex and multiplex
and their average Ct difference between the two was 0.54.
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Efficiency of Reverse Transcription-PCR:
The 10-fold serial dilutions of RNA of quality
control sequence were converted to cDNA by using High
capacity cDNA reverse transcription kit (Applied
Biosystems, Carlsbad, CA). These cDNAs were amplified and
quantified on Q-PCR with the primers/probe for the
lentiviral vector QC. They were compared to the QC DNA
standards (Fig 16). Five experiments were performed on five
different days, and the efficiency of the reverse
transcription kit ranged from 5% to 50% with an average of
20% (Fig 17).
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Fig 16: Standard curve of Lentiviral vector control
sequence template-RNA.
Comparison of Ct values for control sequence template-RNA
that was run Singleplex. The y-axis being the number of RNA
added before Reverse Transcription-PCR and the X-axis being
the Ct values of cDNA amplified on Q-PCR after reverse
transcription. The values of R2, efficiency and slope are an
average of five different experiments.
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Fig 17: Comparison of the DNA copy numbers obtained from
RNA after reverse transcription-PCR.
The output DNA copy number varied with each experiment. For
an input of a 10000 copies the output varied from 5 to 5000
copies. The efficiency of reverse transciption-Q-PCR ranged
from 5%-50% with an average of ~20%.
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Singleplex test on the recombinant adenovirus and
lentivirus:
The wild-type primers/probe were tested on the
virus stocks by lysing them. Ten-fold serial dilutions of
the adenoviral stock were lysed using proteinase K to
disrupt capsid protein (Ma et al., 2001). They were
compared to the wild type template standards on Q-PCR
giving a total virus genome count that was 5 to 12-fold
higher than the infectious titer.
The lentiviral vector was lysed using the
detergent 0.5% Igepal-20 following a 10-fold serial
dilution. They were compared to the standards by Q-PCR,
giving a total virus genome count of 3 x 1011 per ml, which
was 30,000-fold higher than the infectious titer.

p24 assay:
The p24 protein is the HIV viral capsid protein, and
it was assessed using enzyme linked immunosorbent assay.
The quantity of p24 revealed a total virus genome count of
2.7 x 1011 per ml, which was equivalent to the number
obtained through by Q-PCR.
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IV. DISCUSSION

The use of viral vectors for gene therapy has been
studied widely. Viral vectors used in clinical trials, or
in clinically infected animals, tend to distribute to nontarget organs, followed by shedding (Delenda & Gaillard,
2005; Hackett et al., 2000; Heid, et al. 1996; Lizée et
al., 2003). Although the vectors are generally safe, the
potential risk of recombinant virus entering the
environment needs to be assessed for proper biocontainment.
Studies on the shedding of vector viruses are lacking in
the scientific literature. In this study, a Q-PCR assay was
developed to measure the amount of adenoviral and
lentiviral vectors shedding from experimentally infected
animals.
Adenoviral and retroviral vectors are the most
commonly used vectors in gene therapy. The vectors in the
current study were developed from commercially available
kits. For Adenovirus, the infectious titer was determined
by plaque assay and total virus genome count was determined
by Q-PCR. From this, the ratio of total virus genome count
(vg) to infectious viral particle count was calculated.
This ratio reveals the quantity of dead or defective viral
particles, which must be considered for any virus stock.
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Noninfectious particles will contribute to the number of
particles being shed from an animal.
In the current study, the adenoviral vector gave
vg:pfu values of 12:1 and 5:1 for each of two stocks.
Diaconu et al (2010) reported a similar ratio of 10:1 and
4.7:1 for a similar Ad5-based vector. In general, a high
quality batch of the adenoviral vector would have a ratio
less than 30:1 (Ludewig & Hoffmann, 2005).
For the lentiviral vector, the infectious titer was
determined by colony forming unit (cfu) assay and total
virus genome count was determined by Q-PCR. The ratio of
vg:cfu for the lentiviral vector was 30,000:1, suggesting
the presence of a large amount of defective particles. In
general HIV genomes possess large proportion of defective
viral particles and defective particles are mutants of the
virus which might lack one or more gene (Bernier &
Tremblay, 1995; Li et al., 1991). The total virus genome
count was confirmed by measuring concentrations of p24 Gag
protein using enzyme-linked immunosorbent assay. The p24
assay revealed a vg:cfu ratio of 27,000:1. The correlation
between viral titer and p24 protein has been studied. The
p24 protein per particle number is converted to molecules
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per virion by using a molecular weight of 2.4x 104 g mol-1
(Layne et al., 1992).
The use of Real-time PCR for quantification of nucleic
acids is an essential, powerful technique used in a wide
range of analyses. Real-time PCR measures the amount of DNA
produced in the exponential phase of amplification. In
contrast, conventional PCR shows only the end-product of
amplification, frequently in the plateau phase of
amplification. This is why conventional PCR is not
quantitative.
For the quantitative PCR assay in the current study,
primers and probes were designed to amplify and detect the
encapsidation region of Adenovirus type 5 and the RRE
region of HIV-1, strain NL4-3. Because all generations of
adenoviral and lentiviral vectors to date retain these
regions, the primers and probes designed here can be
universally used, assuming the serotype or strain is
similar.
In order to assess the accuracy of the assay, the
unknown sample is spiked with an internal control which
helps the precise quantification. An external control that
was amplified in a separate reaction would not be as
accurate. A known number of molecules are added before the
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processing of an unknown sample and during quantification,
and it is co-amplified in a Q-PCR multiplex reaction. By
using this strategy, the loss of sample during the
processing is accounted for. The quality control sequence
had minimal differences as compared to the wild type
sequence to ensure similar efficiency for a comparable
amplification. The primer binding regions remain the same
for both wild type and quality control sequence. Saulnier
et al (2003) reported the use of an internal control for
adenoviral vectors in their study, but their control was λ
bacteriophage for which primers and a probe were designed.
The quality control sequence to be spiked with the
lentivirus was transcribed into RNA, which was then reverse
transcribed into cDNA. The amplification curve was then
compared to the curve for the DNA standards. In most cases,
the efficiency of reverse transcription (cDNA synthesis) is
often less than 100% and has been reported to be highly
variable (Wong & Medrano, 2005). In the current study, cDNA
was quantified using Q-PCR, and the efficiency of cDNA
synthesis was found to be 20% on average. Since the genetic
material of HIV-1 vector is RNA, it must be converted to
cDNA for Q-PCR. Thus, this step is required, and the
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conversion rate must be accounted for in the quantitative
assay.
With a minimal number of sequence differences in the
probe region of the wild type sequence, a quality control
sequence was designed to spike the unknown samples.
Kawahira et al. (2010), in their study on viral shedding
after adenoviral vector treatment for esophageal cancer,
used conventional PCR to report only the positive or
negative viral DNA in samples. The quantification of the
sample was not performed to show the amount of virus the
patient was shedding.
In the current study, five 10-fold serial dilutions of
the vector DNA of wild type and quality control sequence
were performed in singleplex reactions and optimized along
with their specific primers and probes. The multiplex
format showed that the quality control sequence did not
interfere with amplification of the wild type DNA. This
multiplex format makes use of two assay templates with two
different probes and a single set of primers. Saulnier et
al (2003) made use of the similar principle but they used
completely different assay sets. The multiplex reaction in
the current study clearly showed high specificity and
sensitivity, to which the viral shedding can be compared.
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The standard curves for assessing the wild type and
quality control sequences were generated using a dynamic
range of 4 logs (106 to 102). The upper limit of this range
was chosen based on the observation that Ct values were
approaching the baseline Ct range (generally between cycles
3 and 15). The lower limit of the dynamic range was chosen
based on the observation that Ct values for the 102 standard
were less than or equal to 37. Values of Ct between 37 and
40 were defined as the equivocal range for this study. When
limiting dilutions of DNA and RNA molecules for the
adenoviral and lentiviral systems were performed and
measured by Q-PCR, quantities below 10 (in the 37 to 40 Ct
range) could be detected by extrapolation from the standard
curve. The true limit of detection for viral shedding will
be determined in future experiments using biological
samples spiked with known amounts of virus.
Conclusion and Future studies:
In conclusion, a highly specific, sensitive, and
reproducible assay using Q-PCR to quantify the shedding of
adenoviral and lentiviral vector viruses from excretions of
experimentally infected animals was developed. Future
studies will include testing for replication competent
virus (RCV) in the virus stocks. A multiplex reaction
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performed on biological samples spiked with wild type virus
and quality control sequences will confirm the sensitivity
of the assay. Finally, testing samples obtained from
infected and control research animals will reveal how much
virus is being shed by specific routes of infection using
specific doses for virus for the initial infection.
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V. GLOSSARY
BJ5183-AD-1: Electroporation competent bacterial cells
cDNA: Complementary deoxyribonucleic acid
CFU: Colony forming units
Ct: Threshold cycle
E1,E2,E3,E4: Early transcribed regions of adenovirus
HIV-1: Human immunodeficiency virus-1
PCR: Polymerase chain reaction
PFU: Plaque forming units
pShuttle-CMV-lacZ: Control shuttle vector
QC: Quality control
Q-PCR: Quantitative polymerase chain reaction
R2: Coefficient of determination
RRE: Rev response element
Wt: Wildtype virus
XL-10: Ultracompetent bacterial cells
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